revenue for Q4 2023, with the Company reporting $148.1M (US$97.1M1) of total product revenue, primarily generated from sales of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) in the United States, an increase of 11% on the prior quarter (Q3 2023) total revenue of $133.6M (US$87.2M2).
Growth in Illuccix hasnt petered out at all.
its growing
and 19% increase in dose volume.
gawd
cant complain there can we ....(someone will )
well done CB
i was praying for the magic $150. but hoping not to see and shortfalls. and you've delivered
noice
200% growth in 2023 - hello !?
and its not 200% from smalls ... its half a Billion dollars and growing
revenue for Q4 2023, with the Company reporting $148.1M...
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.48 |
Change
-0.310(1.65%) |
Mkt cap ! $6.184B | |||
| Open | High | Low | Value | Volume |
| $18.66 | $18.85 | $18.48 | $20.76M | 1.116M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13096 | $18.48 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.50 | 1200 | 1 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| TLX (ASX) Chart |